LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Lucid Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.10 (-21.05%)
Close on Oct 19, 2026
- Market cap
- $69.11M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
30.2%
61M of 203M shares
Institutional holders
116
25 new, 10 sold out
Net institutional buying
27M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $245.00K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| PAVmed Inc. | 38,816,903 | 27.50% | 13D (active) amendment | Feb 3, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LUCD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 8,856,844 | 4.36% | $9.48M | New | 0.02% |
| BlackRock, Inc. | 8,373,117 | 4.12% | $8.96M | +3,734,874 | 0.00% |
| Vanguard Capital Management LLC | 6,556,344 | 3.23% | $7.02M | +2,401,574 | 0.00% |
| Two Seas Capital LP | 6,000,000 | 2.95% | $6.42M | +3,000,000 | 0.13% |
| Masters Capital Management LLC | 4,000,000 | 1.97% | $4.28M | – | 0.11% |
| abrdn plc | 3,822,997 | 1.88% | $4.09M | +178,720 | 0.01% |
| Geode Capital Management, LLC | 3,789,948 | 1.86% | $4.06M | +1,544,598 | 0.00% |
| State Street Corp | 2,437,337 | 1.20% | $2.61M | +882,756 | 0.00% |
| First Manhattan Co. LLC. | 2,188,550 | 1.08% | $2.34M | +1,865,100 | 0.01% |
| Wells Fargo & Company/Mn | 2,067,046 | 1.02% | $2.21M | +792,656 | 0.00% |
| Russell Investments Group, Ltd. | 1,651,788 | 0.81% | $1.77M | +68,180 | 0.00% |
| Northern Trust Corp | 1,219,879 | 0.60% | $1.31M | +549,294 | 0.00% |
| Perkins Capital Management Inc | 1,125,000 | 0.55% | $1.20M | −1,000 | 0.91% |
| Vanguard Fiduciary Trust Co | 1,068,109 | 0.53% | $1.14M | +444,552 | 0.00% |
| Vanguard Portfolio Management LLC | 1,022,262 | 0.50% | $1.09M | +493,493 | 0.00% |
| UBS Group AG | 845,314 | 0.42% | $904.49K | +399,835 | 0.00% |
| Aqr Capital Management LLC | 723,200 | 0.36% | $773.82K | +488,431 | 0.00% |
| Raymond James Financial Inc | 577,381 | 0.28% | $617.80K | +52,445 | 0.00% |
| Lido Advisors, LLC | 446,739 | 0.22% | $478.01K | +63,657 | 0.00% |
| Charles Schwab Investment Management Inc | 325,312 | 0.16% | $348.08K | +127,888 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 116 | 61M | 30.2% | 25 / 59 | 13 / 10 | 28M | 1M |
| Q1 2026 | 103 | 36M | 17.5% | 26 / 32 | 19 / 11 | 10M | 2M |
| Q4 2025 | 89 | 32M | 15.8% | 18 / 30 | 16 / 14 | 5M | 8M |
| Q3 2025 | 86 | 35M | 17.3% | 25 / 31 | 11 / 11 | 17M | 1M |
| Q2 2025 | 72 | 19M | 9.3% | 32 / 19 | 6 / 9 | 12M | 3M |
| Q1 2025 | 49 | 9M | 4.6% | 20 / 12 | 8 / 4 | 7M | 1M |
| Q4 2024 | 33 | 3M | 1.6% | 11 / 8 | 8 / 6 | 1M | 0M |
| Q3 2024 | 29 | 2M | 1.2% | 5 / 6 | 8 / 9 | 1M | 0M |
| Q2 2024 | 34 | 2M | 1.0% | 8 / 9 | 8 / 4 | 0M | 0M |
| Q1 2024 | 30 | 2M | 1.0% | 9 / 11 | 8 / 4 | 1M | 0M |
| Q4 2023 | 25 | 2M | 0.9% | 3 / 7 | 7 / 1 | 0M | 0M |
| Q3 2023 | 24 | 2M | 0.9% | 7 / 4 | 5 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LUCD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,547,002 | 2.24% | $4.87M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,567,505 | 1.76% | $3.82M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,861,414 | 0.92% | $1.99M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,578,431 | 0.78% | $1.38M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,396,456 | 0.69% | $1.49M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 507,380 | 0.25% | $522.60K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 497,964 | 0.25% | $532.82K | 0.04% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 459,876 | 0.23% | $473.67K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 362,863 | 0.18% | $316.27K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 277,964 | 0.14% | $297.42K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 195,065 | 0.10% | $170.02K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Equity Fund | 186,569 | 0.09% | $162.61K | 0.02% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 171,254 | 0.08% | $176.39K | 0.00% | May 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 154,902 | 0.08% | $165.75K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 140,008 | 0.07% | $144.21K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lishan Aklog | Chief Executive Officer, Director | 3,636,627 | 1.79% | Feb 24, 2026 |
| Victoria Tou-ho Lee | Chief Medical Officer | 650,000 | 0.32% | Apr 24, 2026 |
| Dennis M. McGrath | Chief Financial Officer | 1,813,569 | 0.89% | Feb 24, 2026 |
| Shaun O'Neil | President and COO | 1,446,763 | 0.71% | Feb 24, 2026 |
| Michael Adam Gordon | General Counsel and Secretary | 1,000,000 | 0.49% | Feb 24, 2026 |
| Dennis Matheis | Director | 1,033,443 | 0.51% | May 21, 2026 |
| Debra White | Director | 235,800 | 0.12% | Feb 24, 2026 |
| James L. Cox | Director | 405,120 | 0.20% | Feb 24, 2026 |
| Ronald M. Sparks | Director | 320,460 | 0.16% | Feb 24, 2026 |
| John R. Palumbo | Director | 338,000 | 0.17% | Feb 24, 2026 |
| Stanley Lapidus | Director | 337,392 | 0.17% | Feb 24, 2026 |
| Jacque J. Sokolov | Director | 320,460 | 0.16% | Feb 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dennis Matheis Director | May 20, 2026 | Buy | +245,000 | $1.00 | $245.00K | 1,033,443 |
| Ronald M. Sparks Director | Feb 20, 2026 | Award | +123,000 | – | – | 320,460 |
| James L. Cox Director | Feb 20, 2026 | Award | +123,000 | – | – | 405,120 |
| Lishan Aklog Chief Executive Officer, Director | Feb 20, 2026 | Award | +2,170,000 | – | – | 3,636,627 |
| John R. Palumbo Director | Feb 20, 2026 | Award | +123,000 | – | – | 338,000 |
| Debra White Director | Feb 20, 2026 | Award | +123,000 | – | – | 235,800 |
| Dennis M. McGrath Chief Financial Officer | Feb 20, 2026 | Award | +470,000 | – | – | 1,813,569 |
| Jacque J. Sokolov Director | Feb 20, 2026 | Award | +123,000 | – | – | 320,460 |
| Shaun O'Neil President and COO | Feb 20, 2026 | Award | +620,000 | – | – | 1,446,763 |
| Stanley Lapidus Director | Feb 20, 2026 | Award | +123,000 | – | – | 337,392 |
| Michael Adam Gordon General Counsel and Secretary | Feb 20, 2026 | Award | +300,000 | – | – | 1,000,000 |
| Dennis Matheis Director | Feb 20, 2026 | Award | +123,000 | – | – | 788,443 |
| Dennis Matheis Director | Aug 20, 2025 | Buy | +100,000 | $1.02 | $102.00K | 665,443 |
| Dennis Matheis Director | May 22, 2025 | Buy | +33,218 | $1.32 | $43.85K | 565,443 |
| Dennis Matheis Director | May 22, 2025 | Buy | +33,218 | $1.32 | $43.85K | 350,000 |
| Dennis Matheis Director | May 21, 2025 | Buy | +129,684 | $1.32 | $171.18K | 532,225 |
| Dennis Matheis Director | May 21, 2025 | Buy | +129,684 | $1.32 | $171.18K | 316,782 |
| Dennis Matheis Director | May 20, 2025 | Buy | +187,098 | $1.30 | $243.23K | 402,541 |
| Dennis Matheis Director | May 20, 2025 | Buy | +187,098 | $1.30 | $243.23K | 187,098 |
| Shaun O'Neil President and COO | Feb 20, 2025 | Award | +300,000 | – | – | 826,763 |
| James L. Cox Director | Feb 20, 2025 | Award | +112,800 | – | – | 282,120 |
| Debra White Director | Feb 20, 2025 | Award | +112,800 | – | – | 112,800 |
| Dennis M. McGrath Chief Financial Officer | Feb 20, 2025 | Award | +300,000 | – | – | 1,343,569 |
| Michael Adam Gordon General Counsel and Secretary | Feb 20, 2025 | Award | +300,000 | – | – | 700,000 |
| Dennis Matheis Director | Feb 20, 2025 | Award | +112,800 | – | – | 162,725 |
| Ronald M. Sparks Director | Feb 20, 2025 | Award | +112,800 | – | – | 197,460 |
| Lishan Aklog Chief Executive Officer, Director | Feb 20, 2025 | Award | +300,000 | – | – | 1,466,627 |
| Jacque J. Sokolov Director | Feb 20, 2025 | Award | +112,800 | – | – | 197,460 |
| Stanley Lapidus Director | Feb 20, 2025 | Award | +112,800 | – | – | 214,392 |
| Shaun O'Neil President and COO | May 7, 2024 | Award | +400,000 | – | – | 526,763 |
| Lishan Aklog Chief Executive Officer, Director | May 7, 2024 | Award | +400,000 | – | – | 1,166,627 |
| Michael Adam Gordon General Counsel and Secretary | May 7, 2024 | Award | +400,000 | – | – | 400,000 |
| Dennis M. McGrath Chief Financial Officer | May 7, 2024 | Award | +400,000 | – | – | 1,043,569 |
| Inc. PAVmed 10% owner | Feb 15, 2024 | Other | −3,331,747 | – | – | 31,302,444 |
| Inc. PAVmed 10% owner | Jan 26, 2024 | Other | +3,331,771 | $1.40 | $4.66M | 34,634,191 |
| Stanley Lapidus Director | Sep 26, 2023 | Sale(10b5-1 plan) | −9,747 | $1.45 | $14.13K | 101,592 |
| Stanley Lapidus Director | Sep 26, 2023 | Sale(10b5-1 plan) | −10,000 | $1.43 | $14.30K | 111,339 |
| Stanley Lapidus Director | Sep 26, 2023 | Sale(10b5-1 plan) | −10,000 | $1.47 | $14.70K | 121,339 |
| Stanley Lapidus Director | Sep 25, 2023 | Sale(10b5-1 plan) | −200 | $1.43 | $286 | 131,339 |
| Stanley Lapidus Director | Sep 21, 2023 | Sale(10b5-1 plan) | −100 | $1.44 | $144 | 131,539 |
| Stanley Lapidus Director | Sep 21, 2023 | Sale | −100 | $1.44 | $144 | 131,539 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale(10b5-1 plan) | −3,405 | $1.45 | $4.94K | 132,051 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale(10b5-1 plan) | −412 | $1.44 | $593 | 131,639 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale | −3,405 | $1.45 | $4.94K | 132,051 |
| Stanley Lapidus Director | Sep 20, 2023 | Sale | −412 | $1.44 | $593 | 131,639 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,479,326 | $1.84 | $2.72M | 31,302,420 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +331,210 | $1.66 | $549.81K | 29,823,094 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +221,952 | $2.48 | $550.44K | 29,491,884 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,145,086 | $1.84 | $2.11M | 29,072,276 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +197,656 | $2.78 | $549.48K | 29,269,932 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +221,952 | $2.48 | $550.44K | 40,672,939 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +331,210 | $1.66 | $549.81K | 41,004,149 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,479,326 | $1.84 | $2.72M | 42,483,475 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +197,656 | $2.78 | $549.48K | 40,450,987 |
| Inc. PAVmed 10% owner | Nov 30, 2022 | Other | +1,145,086 | $1.84 | $2.11M | 40,253,331 |
| Stanley Lapidus Director | Sep 20, 2022 | Sale | −16,864 | $1.70 | $28.67K | 135,456 |
| Stanley Lapidus Director | Sep 20, 2022 | Sale | −17,000 | $1.71 | $29.07K | 152,320 |
| Lishan Aklog Chief Executive Officer, Director | Jan 7, 2022 | Award | +60,000 | – | – | 624,400 |
| Dennis M. McGrath Chief Financial Officer | Jan 7, 2022 | Award | +60,000 | – | – | 624,400 |
| Inc. PAVmed 10% owner | Oct 18, 2021 | Buy | +571,428 | $14.00 | $8.00M | 27,927,190 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| N. Lapidus Stanley Director | Sep 26, 2023 | 33,864 | $49.10K | Sep 26, 2023 | Restricted Stock Grant under Board-Approved Issuer Plan |